Ten reasons for choosing bilastine Review article
Article Sidebar
Published:
Dec 31, 2014
Keywords:
allergy, allergic rhinitis, bilastine
Main Article Content
Abstract
Bilastine is a novel non-sedating histamine H1-receptor antagonist developed for the treatment of allergic rhinoconjunctivitis and urticaria. Bilastine has a similar efficacy to other second-generation H1-receptor. Studies in human volunteers demonstrated that bilastine is rapidly absorbed after oral treatment, reaching maximal plasma concentrations 1–1.5 h after administration. The absorption of bilastine is linear and dose-proportional; it appears to be safe and well tolerated. Multiple administration of bilastine has confirmed the linearity of the kinetic parameters. The safety profile in terms of adverse effects is very similar to placebo. The distribution in the brain is undetectable. Bilastine 20 mg does not increase alcohol effects and is similar to placebo in the driving test.
Article Details
How to Cite
Rapiejko , P. (2014). Ten reasons for choosing bilastine. Medycyna Faktow (J EBM), 7(4(25), 48-52. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2336
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bousquet J., van Cauwenberge P., Khaltaev N.: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001; 108(suppl.): S147-334.
2. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013; S1.
3. Simons F.E., Simons K.J.: Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol. 2011; 128(6): 1139-1150.e4.
4. Criado P.R., Criado R.F., Maruta C.W. et al.: Histamine, histamine receptors and antihistamines: new concepts. An. Bras. Dermatol. 2010; 85: 195-210.
5. Tarchalska-Kryńska B.: Leki przeciwhistaminowe – farmakodynamika i farmakokinetyka. W: Leki przeciwhistaminowe – Stanowisko Grupy Ekspertów Polskiego Towarzystwa Alergologicznego. Górski P., Grzelewska-Rzymowska I., Kruszewski J. (red.). Wyd. Sesja, Łódź 2002: 33-57.
6. Sadaba B., Ramon Azanza J., Gomez-Guiu A. et al.: Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Therapeutics and Clinical Risk Management 2013; 9: 197-205.
7. Jauregizar N., de la Fuente L., Lucero M.L. et al.: Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin. Pharmacokinet. 2009; 48(8): 543-554.
8. Kuna P., Bachert C., Nowacki Z. et al.: Bilastine International Working Group: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy 2009; 39(9): 1338-1347.
9. Horak F., Zieglmayer P., Zieglmayer R. et al.: The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm. Res. 2010; 59(5): 391-398.
10. Corcostegui R., Labeaga L., Innerárity A. et al.: In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs 2006; 7: 219-231.
11. Rapiejko P., Lipiec A.: Bilastyna w leczeniu alergicznego nieżytu nosa. Postęp Derm. Alergol. 2014; XXXI(suppl. 2): s16-27.
12. Scaglione F.: Safety profile of bilastine: 2nd generation H1-antihistamines. Eur. Rev. Med. Pharmacol. Sci. 2012; 16(14): 1999-2005.
13. Pawliczak R.: Bezpieczeństwo nowych leków przeciwhistaminowych. Terapia 2012; 4: 60-66.
14. Montoro J., Mullol J., Davila I. et al.: Bilastine and the central nervous system. J. Investig. Allergol. Clin. Immunol. 2011; 21(suppl. 3): 9-15.
15. García-Gea C., Clos S., Antonijoan R.M. et al.: Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. 20th Congress of the Spanish Clinical Pharmacology Society; Basic Clin. Pharmacol. Toxicol. 2006; 99(suppl. I): 30. Abstract EC13.
16. Bachert C., Kuna P., Sanquer F. et al.: Comparison of the efficacy and safety of bilastine 20 mg vs. desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64: 158-165.
17. Brożek J.L., Bousquet J., Baena‑Cagnani C.E. et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 2010; 126: 466-476.
2. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013; S1.
3. Simons F.E., Simons K.J.: Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol. 2011; 128(6): 1139-1150.e4.
4. Criado P.R., Criado R.F., Maruta C.W. et al.: Histamine, histamine receptors and antihistamines: new concepts. An. Bras. Dermatol. 2010; 85: 195-210.
5. Tarchalska-Kryńska B.: Leki przeciwhistaminowe – farmakodynamika i farmakokinetyka. W: Leki przeciwhistaminowe – Stanowisko Grupy Ekspertów Polskiego Towarzystwa Alergologicznego. Górski P., Grzelewska-Rzymowska I., Kruszewski J. (red.). Wyd. Sesja, Łódź 2002: 33-57.
6. Sadaba B., Ramon Azanza J., Gomez-Guiu A. et al.: Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Therapeutics and Clinical Risk Management 2013; 9: 197-205.
7. Jauregizar N., de la Fuente L., Lucero M.L. et al.: Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin. Pharmacokinet. 2009; 48(8): 543-554.
8. Kuna P., Bachert C., Nowacki Z. et al.: Bilastine International Working Group: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy 2009; 39(9): 1338-1347.
9. Horak F., Zieglmayer P., Zieglmayer R. et al.: The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm. Res. 2010; 59(5): 391-398.
10. Corcostegui R., Labeaga L., Innerárity A. et al.: In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs 2006; 7: 219-231.
11. Rapiejko P., Lipiec A.: Bilastyna w leczeniu alergicznego nieżytu nosa. Postęp Derm. Alergol. 2014; XXXI(suppl. 2): s16-27.
12. Scaglione F.: Safety profile of bilastine: 2nd generation H1-antihistamines. Eur. Rev. Med. Pharmacol. Sci. 2012; 16(14): 1999-2005.
13. Pawliczak R.: Bezpieczeństwo nowych leków przeciwhistaminowych. Terapia 2012; 4: 60-66.
14. Montoro J., Mullol J., Davila I. et al.: Bilastine and the central nervous system. J. Investig. Allergol. Clin. Immunol. 2011; 21(suppl. 3): 9-15.
15. García-Gea C., Clos S., Antonijoan R.M. et al.: Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. 20th Congress of the Spanish Clinical Pharmacology Society; Basic Clin. Pharmacol. Toxicol. 2006; 99(suppl. I): 30. Abstract EC13.
16. Bachert C., Kuna P., Sanquer F. et al.: Comparison of the efficacy and safety of bilastine 20 mg vs. desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64: 158-165.
17. Brożek J.L., Bousquet J., Baena‑Cagnani C.E. et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 2010; 126: 466-476.